■2013年肾脏疾病:改善全球结果(KDIGO)指南建议对所有成人肾移植受者(KTRs)进行他汀类药物治疗。除了年龄<30岁且没有心血管危险因素(CVRF)的人,但未指定治疗中的低密度脂蛋白胆固醇(LDL)目标水平。2018年美国心脏协会(AHA)指南基于具有特定治疗LDL目标的CVRF的个性化方法,解决了普通人群高脂血症的管理。
■根据KDIGO和AHA指南的建议分析血脂异常管理。
这项回顾性研究包括2017年1月至2020年5月在阿卜杜勒阿齐兹国王医学中心接受移植的所有KTR,利雅得,沙特阿拉伯。他汀类药物的处方率一般,根据其CVRF,KTRs中他汀类药物的处方率,以及实现拟议LDL目标的速度,根据AHA的定义,进行了分析。
■共包括287KTR。在214名(74.6%)年龄≥30岁的患者中,80%接受他汀类药物治疗。他汀类药物在93%和96%的患有糖尿病或冠状动脉疾病的KTRs中使用,分别。年龄≥30岁的患者,LDL目标,根据AHA指南,达到62%,目标为2.6mmol/l,19%,目标为1.8mmol/l。他汀类药物治疗导致从基线到移植后12个月的平均LDL值无显著变化(P=0.607),即使仅包括移植后服用他汀类药物的患者(P=0.34).
■通过应用KDIGO准则,在具有多个CVRF和一般KTRs的KTRs中,他汀类药物处方率较高.然而,这些KTRs中有很大一部分没有达到AHA指南提出的LDL目标,提示需要更高强度的他汀类药物来实现这些目标.
UNASSIGNED: The 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines recommends statin treatment for all adult kidney transplant recipients (KTRs), except those aged <30 years of age and without prior cardiovascular risk factors (CVRF), but does not specify on-treatment low-density lipoprotein cholesterol (LDL) target levels. The 2018 American Heart Association (AHA)
guidelines addressed the management of hyperlipidemia in the general population based on an individualized approach of the CVRF with a specific on-treatment LDL target.
UNASSIGNED: To analyze dyslipidemia management according to the recommendations of the KDIGO and AHA guidelines.
UNASSIGNED: This retrospective study included all KTRs who underwent transplantation between January 2017 and May 2020 at King Abdulaziz Medical Center, Riyadh, Saudi Arabia. The rate of statins prescription in general, rate of statins prescription among KTRs per their CVRF, and rate of achieving the proposed LDL goals, as defined by the AHA, were analyzed.
UNASSIGNED: A total of 287 KTRs were included. Of the 214 (74.6%) patients aged ≥30 years, 80% received a statin. Statins were prescribed in 93% and 96% of KTRs with diabetes or coronary artery disease, respectively. In patients aged ≥30 years, LDL targets, per AHA
guidelines, were achieved in 62% with a target of 2.6 mmol/l, and in 19% with a target of 1.8 mmol/l. Statin therapy resulted in non-significant changes in the mean LDL values from baseline to 12 months after transplantation (P = 0.607), even when only patients prescribed statin after transplantation were included (P = 0.34).
UNASSIGNED: By applying the KDIGO
guidelines, a high rate of statin prescriptions was achieved among KTRs with multiple CVRF and KTRs in general. However, a significant proportion of these KTRs did not achieve the LDL targets proposed by the AHA
guidelines, suggesting that higher-intensity statins would be required to achieve these targets.